Drug discovery biotech looking into the ‘dark’ regions of the human genome picks up a $40M+ Series A

Tyler Patchen

News Reporter

While the combo of machine learning and drug discovery has managed to rake in a lot of capital for companies this year, one biotech is looking to the dark side of the genome to stand out.

Nucleome Therapeutics, a UK-based company founded in 2019 and spun off from Oxford University, is seeking to create precision medicines by decoding “dark matter” from the human genome to find targets no one else has gone after. The company has now garnered a £37.5 million ($42.4 million) Series A to advance its disease programs and build out its platform.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

Drug discovery biotech looking into the ‘dark’ regions of the human genome picks up a $40M+ Series A

Tyler Patchen

News Reporter

Unlock this article instantly by becoming a free subscriber.

AbbVie makes second deal in a week, betting $8.7B in cash on CNS biotech Cerevel

Pfizer plans to pull out of BIO, following moves by other large drugmakers to reduce lobbying footprint

Aviv Regev leads Genentech's next revolution with AI

FDA approves Novartis drug for rare blood disorder

FDA sends letter to Novartis over Kymriah manufacturing safety concerns

Early prediction of outcomes in DLBCL clinical trials through MRD testing

Drug dis­cov­ery biotech look­ing in­to the ‘dark’ re­gions of the hu­man genome picks up a $40M+ Se­ries A

Tyler Patchen

News Reporter

Unlock this article instantly by becoming a free subscriber.

Ab­b­Vie makes sec­ond deal in a week, bet­ting $8.7B in cash on CNS biotech Cerev­el

Pfiz­er plans to pull out of BIO, fol­low­ing moves by oth­er large drug­mak­ers to re­duce lob­by­ing foot­print

Aviv Regev leads Genen­tech's next rev­o­lu­tion with AI

FDA ap­proves No­var­tis drug for rare blood dis­or­der

FDA sends let­ter to No­var­tis over Kym­ri­ah man­u­fac­tur­ing safe­ty con­cerns

Ear­ly pre­dic­tion of out­comes in DL­B­CL clin­i­cal tri­als through MRD test­ing

Drug discovery biotech looking into the ‘dark’ regions of the human genome picks up a $40M+ Series A

AbbVie makes second deal in a week, betting $8.7B in cash on CNS biotech Cerevel

Pfizer plans to pull out of BIO, following moves by other large drugmakers to reduce lobbying footprint

Aviv Regev leads Genentech's next revolution with AI

FDA approves Novartis drug for rare blood disorder

FDA sends letter to Novartis over Kymriah manufacturing safety concerns

Early prediction of outcomes in DLBCL clinical trials through MRD testing